Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Prophylaxis of thromboembolism following cardiac valve replacement As conventional tab: 300-600 mg/day in 3-4 divided doses, w/ an oral anticoagulant. Secondary prevention of stroke or TIA As modified-release cap: 200 mg bid. IV Myocardial imaging As adjunct to thallium-201: 0.142 mg/kg/min over 4 min.
Dosage Details
Myocardial imaging
Adult: 0.142 mg/kg/min infused over 4 min (0.567 mg/kg total) as adjunct to thallium-201.

Prophylaxis of thromboembolism following cardiac valve replacement
Adult: As conventional tab: 300-600 mg daily in 3-4 divided doses, given w/ an oral anticoagulant.

Secondary prophylaxis of stroke or transient ischaemic attack
Adult: As modified-release cap: 200 mg bid.
Should be taken on an empty stomach. Take 1 hr before meals. May be taken w/ meals to reduce GI discomfort.
Intravenous: Dilute in at least 1:2 ratio w/ NaCl 0.9% or 0.45%, or dextrose 5% to make a total volume of approx 20-50 mL.
Special Precautions
Patient w/ hypotension, severe coronary artery disease including unstable angina or recent MI, aortic stenosis, decompensated heart failure, coagulation disorder, migraine, myasthenia gravis. Pregnancy and lactation.
Adverse Reactions
Nervous: Headache, dizziness, faintness, seizure.
CV: Hypotension, angina, tachycardia.
GI: Nausea, diarrhoea, vomiting.
Resp: Bronchospasm.
Haematologic: Thrombocytopenia.
Musculoskeletal: Myalgia.
Dermatologic: Rash, urticaria, facial flushing, angioedema.
Potentially Fatal: Cardiac death, MI, ventricular fibrillation, asystole, sinus node arrest, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia (IV).
IV/Parenteral/PO: B
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
Monitor BP, heart rate, ECG, LFT, respiration.
Symptoms: Cardiac death, cardiac arrest, MI, chest pain, angina pectoris, ECG changes, syncope, cerebrovascular events, headache, myalgia, paraesthesia, warm feeling, flushes, sweating, restlessness, weakness, dizziness, hypotension, and tachycardia. Management: Symptomatic treatment. Perform gastric lavage. Administer xanthine derivatives (e.g. aminophylline 75-100 mg) to reverse haemodynamic effects.
Drug Interactions
May increase plasma concentration and CV effects of adenosine. Enhances effects of oral anticoagulants and produces additive effects w/ other anti-platelets (e.g. aspirin). May increase hypotensive effect of BP lowering drugs. May counteract anticholinesterase effect and aggravate myasthenia gravis when used w/ cholinesterase inhibitors. May reduce the efficacy of fludarabine. Reduced absorption w/ antacids. Abolished coronary vasodilation w/ xanthine derivatives (e.g. theophylline, aminophylline, caffeine) during myocardial imaging.
Description: Dipyridamole, a platelet aggregation inhibitor, causes an accumulation of adenosine, adenine nucleotides, and cyclic AMP by inhibiting the activity of adenosine deaminase and phosphodiesterase, thus inhibiting platelet aggregation and producing vasodilation. Addtionally, it stimulates the release of prostacyclin or PGD2 and causes coronary vasodilation.
Absorption: Incompletely absorbed from the GI tract. Time to peak plasma concentrations: Approx 75 min.
Distribution: Widely distributed into body tissues. Crosses the placenta in small amounts and enters breast milk. Volume of distribution: 2-3 L/kg. Plasma protein binding: 91-99%, mainly to α1-acid glycoprotein.
Metabolism: Metabolised in the liver to glucuronide conjugate; may undergo enterohepatic recirculation.
Excretion: Via faeces (as glucuronide conjugates and unchanged drug). Terminal elimination half-life: 10-12 hr.
Chemical Structure

Click on icon to see table/diagram/image
Store between 15-25°C. Do not freeze. Protect from light.
Disclaimer: This information is independently developed by MIMS based on Dipyridamole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Persantin 25/Persantin 75
  • Vasokor
  • Vasotin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in